Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2019-01-30478,2019,Vassilakos 2019 Gynecol Oncol,13000,self-hpv testing; colposcopy VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,30718124,Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,self-hpv testing; colposcopy,Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.,None,NE
2019-01-30478,2019,Vassilakos 2019 Gynecol Oncol,20000,pap cytology + triage with hpv VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,30718124,Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,pap cytology + triage with hpv,Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.,None,NE
2019-01-30478,2019,Vassilakos 2019 Gynecol Oncol,69000,self-hpv testing + triage with colposcopy VERSUS Self-HPV and triage with Pap cytology IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,30718124,Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,self-hpv testing + triage with colposcopy,Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.,Self-HPV and triage with Pap cytology,NW
2019-01-30478,2019,Vassilakos 2019 Gynecol Oncol,Dominated,pap cytology + triage with hpv VERSUS Self-HPV and triage with colposcopy IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,30718124,Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,pap cytology + triage with hpv,Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.,Self-HPV and triage with colposcopy,NW
2019-01-30478,2019,Vassilakos 2019 Gynecol Oncol,Dominated,pap cytology + triage with hpv VERSUS Self-HPV and triage with Pap cytology IN Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,30718124,Healthy; Age- 19 to 40 years; Gender- Female; Country- Switzerland; Other- Non-attendee in cervical cancer screening.,pap cytology + triage with hpv,Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.,Self-HPV and triage with Pap cytology,NW
2019-01-30325,2019,Jendle 2019 Diabetes Technol Ther,19000,hybrid closed-loop system arm VERSUS Standard/Usual Care- continuous subcutaneous insulin infusion IN Specific disease- diabetes; Age- Adult; Gender- Both; Country- Switzerland.,30785311,Specific disease- diabetes; Age- Adult; Gender- Both; Country- Switzerland.,hybrid closed-loop system arm,Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus  Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.,Standard/Usual Care- continuous subcutaneous insulin infusion,NE
2019-01-28710,2019,Girardin 2019 J Viral Hepat,8700,Increased access screening program for Hepatitis C VERSUS Standard/Usual Care- Current screening (venepuncture) IN Healthy; Age- Unknown; Gender- Both; Country- Switzerland; Other- People who inject drugs.,30338887,Healthy; Age- Unknown; Gender- Both; Country- Switzerland; Other- People who inject drugs.,Increased access screening program for Hepatitis C,Increasing hepatitis C virus screening in people who inject drugs in Switzerland  using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.,Standard/Usual Care- Current screening (venepuncture),NE
2018-01-28292,2018,Hirschmann 2018 Oral Oncol,110000,Nivolumab VERSUS Standard/Usual Care- Investigator’s choice/ standard therapy IN Specific disease- Head and Neck Cancer; Age- Adult; Gender- Both; Country- Switzerland.,30527224,Specific disease- Head and Neck Cancer; Age- Adult; Gender- Both; Country- Switzerland.,Nivolumab,Cost-effectiveness of nivolumab in the treatment of head and neck cancer.,Standard/Usual Care- Investigator’s choice/ standard therapy,NE
2018-01-26496,2018,Panje 2018 Radiother Oncol,43000,Local therapy VERSUS Standard/Usual Care- Maintenance Chemotherapy (MC) alone IN Specific disease- Oligometastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC); Age- Adult; Gender- Both; Country- Switzerland.,30104008,Specific disease- Oligometastatic Non-squamous non-small-cell lung cancer; Age- Adult; Gender- Both; Country- Switzerland.,Local therapy,A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).,Standard/Usual Care- Maintenance Chemotherapy (MC) alone,NE
2018-01-25589,2018,Stollenwerk 2018 Pharmacoeconomics,2100,"Etecalcetide VERSUS Cinacalcet IN Specific disease- Secondary hyperparathyroidism; Age- Adult; Gender- Both; Country- Italy, Spain, Portugal, Switzerland, Czech Republic; Other- Hemodialysis patients.",29392552,"Specific disease- Secondary hyperparathyroidism; Age- Adult; Gender- Both; Country- Italy, Spain, Portugal, Switzerland, Czech Republic; Other- Hemodialysis patients.",Etecalcetide,A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.,Cinacalcet,NE
2017-01-25822,2017,Ademi 2017 Swiss Med Wkly,46000,"Sacubitril/valsartan and standard care VERSUS Angiotensin-converting enzyme inhibitors (ACEIs) and standard care IN Specific disease- Heart failure with reduced ejection fraction; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland.",29185253,"Specific disease- Heart failure with reduced ejection fraction; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland.",Sacubitril/valsartan and standard care,Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.,Angiotensin-converting enzyme inhibitors (ACEIs) and standard care,NE
2017-01-24853,2017,Wein 2017 Int J Cardiol,Dominated,"Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Switzerland; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",28823409,"Specific disease- Acute coronary syndrome; Age- Adult; Gender- Both; Country- Switzerland; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",Basket-Prove II with Prasugrel,Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.,Basket-Prove I with Clopidogrel,NW
2017-01-24853,2017,Wein 2017 Int J Cardiol,Dominated,"Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Denmark; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",28823409,"Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Denmark; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",Basket-Prove II with Prasugrel,Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.,Basket-Prove I with Clopidogrel,NW
2017-01-24853,2017,Wein 2017 Int J Cardiol,Dominated,"Basket-Prove II with Prasugrel VERSUS Basket-Prove I with Clopidogrel IN Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Germany; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",28823409,"Specific disease- Acute coronary syndromes; Age- Adult; Gender- Both; Country- Germany; Other- ST-elevation myocardial infarction (STEMI), a Non-STEMI or Unstable Angina and underwent Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) implantation.",Basket-Prove II with Prasugrel,Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness  analysis from the BASKET-PROVE cohorts.,Basket-Prove I with Clopidogrel,NW
2017-01-24063,2017,Aichmair 2017 Eur Spine J,390000,"Surgery VERSUS Standard/Usual Care- Conservative treatment IN Specific disease- Lumbar Spinal Stenosis (LSS); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland; Other- Patients with the diagnosis of LSS, with a minimum age of 50 years, neurogenic claudication, available magnetic resonance and/or computed tomography imaging studies, and an absence of vertebral fractures, spine infection, scoliosis, or clinically relevant peripheral artery occlusive disease.",28040872,"Specific disease- Lumbar Spinal Stenosis (LSS); Age- 41 to 64 years, >=65 years; Gender- Both; Country- Switzerland; Other- Patients with the diagnosis of LSS, with a minimum age of 50 years, neurogenic claudication, available magnetic resonance and/or computed tomography imaging studies, and an absence of vertebral fractures, spine infection, scoliosis, or clinically relevant peripheral artery occlusive disease.",Surgery,Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS).,Standard/Usual Care- Conservative treatment,SW
2017-01-23911,2017,Hunt 2017 Diabetes Obes Metab,15000,Liraglutide VERSUS lixisenatide 20 ug IN Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Type 2 diabetes failing to achieve glycaemic control on meformin monotherapy.,28124820,Specific disease- Type 2 diabetes; Age- Adult; Gender- Both; Country- United Kingdom (UK); Other- Type 2 diabetes failing to achieve glycaemic control on meformin monotherapy.,Liraglutide,Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.,lixisenatide 20 ug,NE
2017-01-23725,2017,von Dach 2017 Clin Microbiol Infect,640000,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Infections associated with deep-seated foci.,28232163,Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Infections associated with deep-seated foci.,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment,Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.,Linezolid (600 mg twice daily),SW
2017-01-23725,2017,von Dach 2017 Clin Microbiol Infect,Cost-Saving,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland.,28232163,Specific disease- Methicillin-resistant staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland.,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment,Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.,Linezolid (600 mg twice daily),SE
2017-01-23725,2017,von Dach 2017 Clin Microbiol Infect,Cost-Saving,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Non-severe infections.,28232163,Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Non-severe infections.,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment,Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.,Linezolid (600 mg twice daily),SE
2017-01-23725,2017,von Dach 2017 Clin Microbiol Infect,Cost-Saving,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment VERSUS Linezolid (600 mg twice daily) IN Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Severe MRSA infection.,28232163,Specific disease- Methicillin-resistant Staphylococcus aureus infection; Age- Adult; Gender- Both; Country- Switzerland; Other- Severe MRSA infection.,Trimethoprim-sulfamethoxazole (TMP-SMX) + rifampicin (RMP) treatment,Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus  infection: a healthcare system perspective.,Linezolid (600 mg twice daily),SE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
